PSMD10 and nonpapillary renal cell carcinoma: Furthermore, IP assays showed that recombinant CCL24 treatment enhanced the binding of gankyrin to STAT3 in ccRCC, whereas SB328437 inhibited this interaction (Fig. 5k;, Supplementary Fig. S5i).